Vorasidenib significantly improved median progression-free survival and time to next intervention in IDH-mutant grade 2 ...

A new Lancet Oncology Commission highlights a growing "human crisis" in cancer care. Despite advances in treatment and ...

"These longer-term results from the INDIGO trial build upon VORANIGO's previously demonstrated clinical benefits and ...

Amid unprecedented scientific progress in oncology, a growing body of evidence reveals a parallel and profound crisis in the human experience of cancer care. Despite overall survival outcomes ...

We thank Yutaka Shimazu for his insightful comments. We agree that our positive findings1–4 highlight the urgent need for further work on biomarkers of neuronal damage and immune mechanisms in ...